Sarepta Therapeutics
SRPT
409 hedge funds and large institutions have $11.9B invested in Sarepta Therapeutics in 2020 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 129 increasing their positions, 130 reducing their positions, and 44 closing their positions.
102% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 44
64% more capital invested
Capital invested by funds: $7.21B → $11.9B (+$4.64B)
26% more call options, than puts
Call options by funds: $311M | Put options by funds: $247M
12% more funds holding
Funds holding: 366 → 409 (+43)
0.04% more ownership
Funds ownership: 94.76% → 94.8% (+0.04%)
1% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 130
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$113M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$68.7M |
| 4 |
BlackRock
New York
|
+$65.9M |
| 5 |
JP Morgan Chase
New York
|
+$59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$126M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$54.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$52.2M |
| 4 |
RI
RTW Investments
New York
|
-$51.8M |
| 5 |
O
OrbiMed
New York
|
-$46.6M |
SRPT Hedge Fund Activity: Q2 2020 in Review
409 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2020, worth a combined $11.9B — up 64% from $7.21B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new SRPT positions and 44 closed out — a net gain of 45 holders — while 129 added to existing stakes and 130 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $113M. The largest seller was Adage Capital Partners, cutting an estimated $126M.
- 409 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2020, up from 366 in Q1 2020.
- Funds reported $11.9B of Sarepta Therapeutics stock for Q2 2020, up 64% quarter-over-quarter.
- 89 funds opened new Sarepta Therapeutics positions in Q2 2020 and 44 closed out, a net change of +45 holders.
- The largest Sarepta Therapeutics buyer in Q2 2020 was Capital Research Global Investors, an estimated $113M added.
- The largest Sarepta Therapeutics seller in Q2 2020 was Adage Capital Partners, an estimated $126M sold.
Based on aggregated 13F filings for Q2 2020.